Related references
Note: Only part of the references are listed.Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers
Patrick Lyden et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant
A. von Drygalski et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Antibody SPC-54 provides acute in vivo blockage of the murine protein C system
Laurent Burnier et al.
BLOOD CELLS MOLECULES AND DISEASES (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu et al.
NATURE MEDICINE (2013)
Identifying Major Hemorrhage with Automated Data: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)
Guneet K. Jasuja et al.
THROMBOSIS RESEARCH (2013)
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity
Hartmut Geiger et al.
NATURE MEDICINE (2012)
Platelet Factor 4 Inhibits Thrombomodulin-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) by Thrombin
Laurent O. Mosnier
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Engineering Kunitz Domain 1 (KD1) of Human Tissue Factor Pathway Inhibitor-2 to Selectively Inhibit Fibrinolysis PROPERTIES OF KD1-L17R VARIANT
Madhu S. Bajaj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Factor V Is an Anticoagulant Cofactor for Activated Protein C during Inactivation of Factor Va
Thomas J. Cramer et al.
pathophysiology of haemostasis and thrombosis (2010)
Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va
Andrew J. Gale et al.
PROTEIN SCIENCE (2010)
Factor V Leiden and hemophilia
Massimo Franchini et al.
THROMBOSIS RESEARCH (2010)
Species-specific anticoagulant and mitogenic activities of murine protein S
Jose A. Fernandez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Evaluation of a New Hemostatic Agent Ankaferd Blood Stopper in Experimental Liver Laceration
Kemal Karakaya et al.
JOURNAL OF INVESTIGATIVE SURGERY (2009)
INCREASE IN ACTIVATED PROTEIN C MEDIATES ACUTE TRAUMATIC COAGULOPATHY IN MICE
Brian B. Chesebro et al.
SHOCK (2009)
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions
Laurent O. Mosnier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Endotoxemia and sepsis mortality reduction by non-anticoagulant-activated protein C
Edward J. Kerschen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Factor V Leiden improves in vivo hemostasis in murine hemophilia models
A Schlachterman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity
LO Mosnier et al.
BLOOD (2004)
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
GR Bernard et al.
CRITICAL CARE (2003)
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
AJ Gale et al.
PROTEIN SCIENCE (2002)
The Calibrated Automated Thrombogram (CAT):: A universal routine test for hyper- and hypocoagulability
HC Hemker et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2002)
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke
M Shibata et al.
CIRCULATION (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
